Category: Metabolic Therapeutics
GLP-1, GIP, glucagon and related metabolic research programmes, mechanisms and clinical evidence.
GLP-1 Medicines in Australia (2026): TGA Approval, PBS Access and Safety Updates
A dated, source-linked guide to GLP-1 medicines in Australia: TGA-approved indications, PBS access, Wegovy’s listing status and 2026 safety updates.
Read analysis →GLP-3 Australia: What the Term Means, Retatrutide Evidence and TGA Status
What “GLP-3 Australia” usually means, why the term is informal, how it maps to retatrutide’s three receptor targets, and the current TGA position.
Read analysis →CagriSema REIMAGINE 2: What the Published Phase 3 Trial Shows
REIMAGINE 2 published results: HbA1c, safety and trial limits, with sponsor headlines compared against the peer-reviewed phase 3 paper.
Read analysis →Wegovy HD: What the FDA’s 7.2 mg Semaglutide Approval Means—and What It Does Not
The FDA approved a higher-dose semaglutide injection in March 2026. Here is the regulatory fact pattern, safety context and Australian caveat.
Read analysis →Tirzepatide vs Semaglutide: What the SURMOUNT-5 Head-to-Head Trial Actually Shows
A careful reading of SURMOUNT-5: design, 72-week weight outcomes, waist outcomes, safety, funding and the limits of one open-label comparison.
Read analysis →Retatrutide Mechanism: What Triple GIP, GLP-1 and Glucagon Agonism Means
A receptor-by-receptor explanation of retatrutide, separating established human observations from preclinical mechanisms and popular oversimplifications.
Read analysis →Retatrutide Trial Tracker: Phase 2 Evidence, Phase 3 Results and Regulatory Status
Updated 6 October 2026: peer-reviewed TRIUMPH-1 Phase 3 results, estimand differences, the wider trial programme, safety findings and current Australian regulatory status.
Read analysis →